Table 3. Relationship between patterns of contrast-enhancement and WHO histologic subtypes.
| Variable | A (n = 7) | AB (n = 26) | B1 (n = 22) | B2 (n = 24) | B3 (n = 15) | Thymic Carcinoma (n = 47) | P-value |
|---|---|---|---|---|---|---|---|
| CEmax | |||||||
| Mean ± sd(HU) | 41.1 ± 15.8a | 33.0 ± 9.6b | 23.0 ± 8.7c | 22.0 ± 8.2c | 20.9 ± 9.5c | 23.6 ± 9.1c | 0.000* |
| Pattern of CE - no.(%) | 0.000† | ||||||
| Mild | — | 2(8) | 10(45.5) | 14(58) | 8(53) | 16(34) | |
| Moderate | 3(43) | 15(57) | 10(45.5) | 9(38) | 6(40) | 29(62) | |
| Strong | 4(57) | 9(35) | 2(9) | 1(4) | 1(7) | 2(4) |
*P-values were calculated by one-way ANOVA; the different alphabet represented a significant difference between the two groups;
†P-values were calculated by Monte Carlo Test.
CEmax: maximal contrast-enhanced range; CE: contrast enhancement.